Monoamine Oxidase Inhibitors: Safety and Efficacy Issues

1988 ◽  
Vol 22 (3) ◽  
pp. 232-235 ◽  
Author(s):  
Candace S. Brown ◽  
Stephen G. Bryant
Keyword(s):  
Monoamine Oxidase ◽  
Tricyclic Antidepressants ◽  
Hypertensive Crisis ◽  
Endogenous Depression ◽  
Monoamine Oxidase Inhibitors ◽  
Future Research ◽  
Second Line ◽  
Atypical Depression ◽  
Safety And Efficacy ◽  
Treatment Of Depression

Controversy has historically centered on the use of monoamine oxidase inhibitors (MAOI) in the treatment of depression because of safety and efficacy issues. Hypertensive crisis following ingestion of foods containing tyramine is the most feared problem associated with MAOI therapy. The authors conclude that only four tyramine-containing foods clearly warrant absolute prohibition, but indicate situations where moderation should apply. Although MAOI remain second-line agents in the treatment of endogenous depression, it is unclear whether MAOI or tricyclic antidepressants should be the drugs of choice in atypical depression and this question necessitates future research.

Treatment of Depression in Huntington's Disease with Monoamine Oxidase Inhibitors

1986 ◽  
Vol 149 (5) ◽  
pp. 654-656 ◽  
Author(s):  
M. F. Ford
Keyword(s):  
Monoamine Oxidase ◽  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Tricyclic Antidepressants ◽  
Monoamine Oxidase Inhibitors ◽  
Treatment Of Depression

Depression is common in Huntington's disease. It is customary to treat such patients with tricyclic antidepressants, although there is disagreement about their effectiveness. The use of monomine oxidase inhibitors for depression in HD has not previously been reported; three cases are described here. MAOIs appear to be of value in the management of depression in HD.

Monoamine Oxidase Inhibitors: Rehabilitation from Recent Research?

1989 ◽  
Vol 154 (3) ◽  
pp. 287-291 ◽  
Author(s):  
David Nutt ◽  
Paul Glue
Keyword(s):  
Monoamine Oxidase ◽  
Research Council ◽  
Tricyclic Antidepressants ◽  
Medical Research Council ◽  
Monoamine Oxidase Inhibitors ◽  
Second Line ◽  
Dietary Restrictions ◽  
Medical Research Council Trial ◽  
Long Time ◽  
Resistant Depression

For a long time, monoamine oxidase inhibitors (MAOIs) have been the Cinderella drugs of psycho-pharmacy. Although they were introduced just before the tricyclic antidepressants (TCAs), they rapidly became second-line treatments. Several factors contributed to this, in particular the dietary restrictions, the scattered reports of death from overdose and/or toxic interactions, and the unfavourable reports on the efficacy of phenelzine in depression from, among others, the Medical Research Council trial (1965). For a number of years afterwards, prescription of these drugs was limited to a few enthusiasts. More recently, however, their popularity has increased owing firstly to a re-evaluation of their effectiveness in tricyclic-resistant depression and in anxiety disorders, and secondly to growing awareness of the exaggerated claims made about their dangerousness (Pare, 1985).

Monoamine Oxidase Inhibitors: Perspective Design for the Treatment of Depression and Neurological Disorders

2016 ◽  
Vol 12 (2) ◽  
pp. 115-122 ◽  
Author(s):  
Bijo Mathew ◽  
Githa E. Mathew ◽  
Jerad Suresh ◽  
Gülberk Ucar ◽  
Rani Sasidharan ◽  
...  
Keyword(s):  
Monoamine Oxidase ◽  
Neurological Disorders ◽  
Monoamine Oxidase Inhibitors ◽  
Treatment Of Depression

Monoamine Oxidase Inhibitors and Weight Gain

1988 ◽  
Vol 22 (10) ◽  
pp. 755-759 ◽  
Author(s):  
Thomas G. Cantú ◽  
Joan S. Korek
Keyword(s):  
Weight Gain ◽  
Literature Review ◽  
Monoamine Oxidase ◽  
Tricyclic Antidepressants ◽  
Monoamine Oxidase Inhibitors ◽  
Weight Changes ◽  
Appetite Control ◽  
Drug Induced ◽  
Relative Potential ◽  
Induce Weight Gain

Weight gain associated with antidepressant therapy is a common problem that often results in noncompliance. Some authors suggest that monoamine oxidase inhibitors (MAOI) are less likely to produce weight gain than tricyclic antidepressants. This paper addresses the relative potential for weight gain with the MAOI. Assessing the potential for antidepressant-induced weight gain necessitates separating the weight changes associated with alterations in mood disorders from those due to drug-induced alterations in appetite control. The mechanisms of appetite control are reviewed briefly followed by proposed mechanisms by which the MAOI may alter this control. A literature review suggests that phenelzine is the MAOI most likely to induce weight gain; reports of isocarboxazid-induced weight gain are less common. There are no cases of tranylcypromine-induced weight gain in the literature that are clearly associated with the drug. The MAOI probably have different effects on the mechanisms of appetite control.

Management of Depression, Part 2: Treatment Options

2018 ◽  
Author(s):  
Michael Banov
Keyword(s):  
Monoamine Oxidase ◽  
Mental Health Professionals ◽  
Serotonin Reuptake ◽  
Tricyclic Antidepressants ◽  
Antidepressant Medication ◽  
Monoamine Oxidase Inhibitors ◽  
Serotonin Reuptake Inhibitors ◽  
Clinical Depression ◽  
Depression Treatment ◽  
Norepinephrine Reuptake

Clinical depression is a commonly occurring and profoundly disabling condition that affects approximately 4%, or nearly 350 million people, worldwide according to the World Health Organization. Managing depression is challenging due to the marked variability in biological contributors, the heterogeneity of the illness, psychosocial history, current stresses exacerbating the condition, medical and psychiatric co-occurring conditions, lifestyle, and motivation and willingness to accept and engage in treatment recommendations. Mental health professionals such as master-level counselors, psychologists, or psychiatrists are specially trained to identify and treat depression; however, a significant amount of depression presents in primary care medical settings. This review covers treatment of depression with psychotherapy, complementary and alternative medicine (CAM), and antidepressant medication, as well as treatment course and long-term depression treatment. Tables list CAM depression treatments, nonnutraceutical CAM therapies, managing antidepressant side effects, tricyclic antidepressants, serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, norepinephrine dopamine reuptake inhibitor, alpha2 antagonists, serotonin-2 antagonist/reuptake inhibitors, monoamine oxidase inhibitors, food restrictions with monoamine oxidase inhibitors, managing partial response/treatment-resistant depression, and serotonin receptor modulators.   This review contains 15 tables and 98 references Key words: antidepressant medication, clinical depression, depression, monoamine oxidase inhibitors, nonpharmacologic depression treatment, omega-3 fatty acids, S-adenosylmethionine, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, St. John’s wort, tricyclic antidepressants

The Present Status of Monoamine Oxidase Inhibitors

1985 ◽  
Vol 146 (6) ◽  
pp. 576-584 ◽  
Author(s):  
C. M. B. Pare
Keyword(s):  
Monoamine Oxidase ◽  
Present Status ◽  
Monoamine Oxidase Inhibitors ◽  
The Past ◽  
Depressed Patients ◽  
Treatment Of Depression ◽  
Dietary Interactions ◽  
Specific Inhibitors

SummaryThe present status of monoamine oxidase inhibitors in the treatment of depression is reviewed. With adequate doses they are effective antidepressants, but dosages have in the past been too low. Provided proper dietary precautions are taken, the incidence of fatality from dietary interactions is very small and should not deter doctors from using these drugs, especially in those depressed patients who do not respond to tricyclic-type antidepressants. The present status of combining monoamine oxidase inhibitors with tricyclics is discussed, as are the newer specific inhibitors particularly clorgyline and deprenyl.

Tyramine and New Monoamine Oxidase Inhibitor Drugs

1989 ◽  
Vol 155 (S6) ◽  
pp. 32-37 ◽  
Author(s):  
G.M. Simpson ◽  
J. de Leon
Keyword(s):  
Monoamine Oxidase ◽  
Tricyclic Antidepressants ◽  
Monoamine Oxidase Inhibitor ◽  
Relative Effectiveness ◽  
Hypertensive Crisis ◽  
Oxidase Inhibitor ◽  
Monoamine Oxidase A ◽  
Pressor Test ◽  
The World ◽  
Tyramine Pressor Test

The hypertensive crisis induced by the ingestion of cheese in subjects undergoing treatment with monoamine oxidase inhibitors (MAOIs) led to their virtual disappearance in many parts of the world. Three strategies to try and diminish the risk of this reaction have been developed: the combination of current (irreversible and non-selective) MAOIs with tricyclic antidepressants, the use of new selective MAOIs, and the use of new reversible MAOIs. The relative effectiveness of these different approaches can be assessed by the tyramine pressor test. The introduction of reversible and selective monoamine oxidase-A (MAO-A) inhibitors looks especially promising clinically.

Dépression Atypique: Évolution Vers Un Traitement Pharmacologique Spécifique Et Efficace?

1995 ◽  
Vol 40 (2) ◽  
pp. 102-108 ◽  
Author(s):  
Benoit Dassylva ◽  
Réjean Fontaine
Keyword(s):  
Major Depression ◽  
Panic Disorder ◽  
Monoamine Oxidase ◽  
Present Article ◽  
Tricyclic Antidepressants ◽  
Response To Treatment ◽  
Atypical Depression ◽  
Traitement Pharmacologique ◽  
Specific Meaning ◽  
Worse Prognosis

The present article reviews different concepts of atypical depression. Of these, major depression associated with panic disorder would have a specific meaning according to some pharmacological and prognosis studies. It seems that this type of depression is quite frequent and has a significantly worse prognosis than major depression alone. Controlled studies comparing the efficacy of tricyclic antidepressants to phenelzine concluded in favour of the latter in general. It is generally thought that atypical depression would respond better to monoamine oxidase inhibitors(MAOI), but it would seem that it is mainly major depression associated with panic disorder that could predict this kind of response to treatment. Second generation antidepressants have not been studied systematically for this purpose even though preliminary reports seem promising.

Sign in / Sign up

Export Citation Format

Share Document